for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ChemoCentryx Inc

CCXI.OQ

Latest Trade

59.99USD

Change

-0.01(-0.02%)

Volume

193,949

Today's Range

59.42

 - 

62.32

52 Week Range

6.17

 - 

63.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

ChemoCentryx Says Entered Product Agreement With Patheon

May 14 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX SAYS ON MAY 8 CO ENTERED INTO PRODUCT AGREEMENT WITH PATHEON WHICH WAS MADE AS PER A MASTER MANUFACTURING SERVICES AGREEMENT DATED MARCH 18.CHEMOCENTRYX INC - UNDER MASTER AGREEMENT AND PRODUCT AGREEMENT, PATHEON HAS AGREED TO MANUFACTURE AND SUPPLY AVACOPAN DRUG PRODUCT.CHEMOCENTRYX INC - PRODUCT AGREEMENT HAS AN INITIAL TERM THAT EXPIRES ON DECEMBER 31, 2026.CHEMOCENTRYX INC - MASTER AGREEMENT HAS AN INITIAL TERM THAT EXPIRES ON MARCH 18, 2023.

Chemocentryx Reports Qtrly Loss Per Share $0.26

March 10 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 REVENUE $10 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9.7 MILLION.QTRLY LOSS PER SHARE $0.26.Q4 EARNINGS PER SHARE VIEW $-0.26 -- REFINITIV IBES DATA.

ChemoCentryx Reports Third Quarter 2019 Financial Results

Nov 4 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q3 REVENUE $10.6 MILLION VERSUS $9.0 MILLION.Q3 REVENUE ESTIMATE $7.7 MILLION -- REFINITIV IBES DATA.$205 MILLION IN CASH AND INVESTMENTS AT SEPTEMBER 30, 2019.EXPECTS TO CLOSE 2019 WITH CASH AND INVESTMENTS IN EXCESS OF $185 MILLION.QTRLY LOSS PER SHARE $0.22.Q3 EARNINGS PER SHARE VIEW $-0.28 -- REFINITIV IBES DATA.

Chemocentryx Posts Q2 Revenue Of $7.2 Million Versus $15 Million

Aug 5 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q2 REVENUE $7.2 MILLION VERSUS $15 MILLION.Q2 REVENUE ESTIMATE $9.8 MILLION -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $223.1 MILLION AT JUNE 30, 2019.QTRLY LOSS PER SHARE $0.26.Q2 EARNINGS PER SHARE VIEW $-0.22 -- REFINITIV IBES DATA.TOPLINE DATA FROM PIVOTAL ADVOCATE PHASE III TRIAL OF C5A RECEPTOR INHIBITOR AVACOPAN IN ANCA VASCULITIS ON TRACK FOR Q4 2019.

ChemoCentryx Reports Qtrly Loss Per Share $0.23

May 6 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q1 REVENUE $8.3 MILLION VERSUS $9.5 MILLION.Q1 REVENUE ESTIMATE $11 MILLION -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $234.1 MILLION AT MARCH 31, 2019.COMPANY EXPECTS TO UTILIZE CASH AND INVESTMENTS IN RANGE OF $75.0 MILLION TO $85.0 MILLION IN 2019.QTRLY LOSS PER SHARE $0.23.Q1 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $11.0 MILLION -- REFINITIV IBES DATA.

ChemoCentryx Says Co Sold 4.8 Mln Shares Of Its Common Stock Pursuant To Its Equity Distribution Agreement With Piper Jaffray On March 25

March 26 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX INC - ON MARCH 25, COMPANY SOLD 4.8 MILLION SHARES OF ITS COMMON STOCK PURSUANT TO ITS EQUITY DISTRIBUTION AGREEMENT WITH PIPER JAFFRAY & CO.CHEMOCENTRYX INC - SOLD COMMON STOCK AT A PRICE PER SHARE OF $11.40.

Chemocentryx Posts Qtrly Loss Per Share Of $0.21

March 11 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 REVENUE $9.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9.4 MILLION.QTRLY LOSS PER SHARE $0.21.EXPECTS TO UTILIZE CASH AND INVESTMENTS IN RANGE OF $75.0 MILLION AND $85.0 MILLION IN 2019.

ChemoCentryx Announces Withdrawal of Phase II-Based CMA Application for ANCA-Associated Vasculitis in Europe

Jan 24 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX ANNOUNCES WITHDRAWAL OF PHASE II-BASED CONDITIONAL MARKETING AUTHORIZATION (CMA) APPLICATION FOR ANCA-ASSOCIATED VASCULITIS IN EUROPE; PHASE III ADVOCATE TRIAL DATA RELEASE PLANNED FOR Q4 2019.CHEMOCENTRYX INC - IN LIGHT OF UPCOMING AVAILABILITY OF DATA FROM PIVOTAL PHASE III ADVOCATE TRIAL DECIDED TO WITHDRAW CMA OF AVACOPAN.CHEMOCENTRYX INC - DECIDED TO WITHDRAW APPLICATION CMA OF AVACOPAN FOR TREATMENT OF ANCA-ASSOCIATED VASCULITIS BASED ON PHASE II DATA.CHEMOCENTRYX INC - DECIDED NOT TO PROCEED WITH LIMITED PHASE II-BASED CMA IN EUROPE.CHEMOCENTRYX - EFFORTS TO NOW BE DIRECTED TO FILE INTEGRATED REGULATORY SUBMISSIONS IN 2020 WITH EMA, FDA FOR FULL (UNCONDITIONAL) MARKETING APPROVAL.

Chemocentryx Files For Offer & Sell Up To $75 Mln Of Shares Of Stock

Dec 4 (Reuters) - ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX INC FILES FOR OFFER AND SELL UP TO $75.0 MILLION OF SHARES OF COMMON STOCK - SEC FILING.

Chemocentryx - QTRLY Loss Per Share $0.22

ChemoCentryx Inc <CCXI.O>::CHEMOCENTRYX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q3 REVENUE $9.0 MILLION.Q3 REVENUE VIEW $11.9 MILLION -- THOMSON REUTERS I/B/E/S.CHEMOCENTRYX - QTRLY LOSS PER SHARE $0.22.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up